Related Experiment Video
Updated: May 26, 2025
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
Published on: January 29, 2016
Effect of adaptive variable-resistance training on chemotherapy-induced sarcopenia, fatigue, and functional
Ragab K Elnaggar1,2,3, Waleed S Mahmoud4,5, Mohamed S Abdrabo5,6
1Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia. rke_pt2001@yahoo.com.
Purpose:
With the rising survival rate among children and adolescents with acute lymphoblastic leukemia (ALL), prioritizing patient-centered care to address the long-term effects of chemotherapy through tailored rehabilitation interventions is essential for optimizing their quality of life. The purpose of this study was to investigate the impact of an 8-week intervention using adaptive variable-resistance training (Adaptive-VRT) on chemotherapy-induced sarcopenia, fatigue, and functional restrictions in pediatric survivors of ALL.
Methods:
A prospective randomized controlled trial included a total of 62 survivors of ALL, aged 12-18 years, and completed maintenance chemotherapy. Participants were randomized into two groups: the Adaptive-VRT group (n = 31), assigned the Adaptive-VRT intervention, and the control group (n = 31), which adhered to the standard exercise protocol. Baseline and post-intervention measurements were undertaken to analyze sarcopenia-related variables (i.e., muscle thickness and muscle strength), fatigue, and functional performance.
Results:
The Adaptive-VRT group exhibited more favorable changes in muscle thickness [thigh thickness (P < .001; η2P = 0.32); rectus femoris (P < .001; η2P = 0.21); vastus intermedius (P = .002; η2P = 0.15)], and peak concentric torque of quadriceps [at speed of 90°/s (P = .005; η2P = 0.13), 120°/s (P = .021; η2P = 0.10), or 180°/s (P = .008; η2P = 0.11)] in comparison with the control group. Additionally, the Adaptive-VRT group reported lower fatigue levels (P = .031; η2P = 0.08) and demonstrated better functional performance [6-min walk test (P < .001; η2P = 0.25), 4 × 10-m shuttle running test (P < .001; η2P = 0.24), as well as timed up and down stairs (P < .0006; η2P = 0.18)].
Conclusion:
The findings suggest that Adaptive-VRT is a promising intervention for ameliorating chemotherapy-induced sarcopenia, fatigue, and functional limitations in pediatric ALL survivors.
Trial Registration:
ClinicalTrials.gov Identifier: NCT06338020.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Cancer Survival Analysis